NCT00723190 - Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

303

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

June 30, 2010

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

CLONICEL (Clonidine HCl sustained release)

0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4

Trial Locations (27)

21208

Baltimore

27514

Chapel Hill

27705

Durham

28209

Charlotte

32216

Jacksonville

32607

Gainesville

32806

Orlando

33161

Miami

33319

Lauderhill

34208

Bradenton

40004

Bardstown

44106

Cleveland

48307

Rochester Hills

63005

St Louis

72205

Little Rock

73103

Oklahoma City

73116

Oklahoma City

77007

Houston

77488

Wharton

77566

Lake Jackson

84015

Clinton

92103

San Diego

92243

El Centro

92612

Irvine

98033

Kirkland

08043

Voorhees Township

08046

Willingboro